Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: A sub analysis of the CANDLE trial
Cardiovascular Diabetology — Kusunose K, Imai T, Tanaka A, et al. | September 17, 2021
Canagliflozin exhibited a trend of lower NT-pro BNP levels in the subgroup with lower left ventricular (LV) diastolic function compared with glimepiride.
According to the findings of this investigation, the positive benefits of canagliflozin treatment may change depending on the severity of LV diastolic dysfunction.
In the CANDLE trial, patients (n = 233) were randomly assigned to either an add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120).
The geometric mean change in NT-proBNP level from baseline to 24 weeks in the canagliflozin group was 0.98 and 1.07 in the glimepiride group.
The change ratio with canagliflozin/glimepiride was 0.93.
The reaction of an increase in NT-proBNP levels was investigated using responder analyses.
Although the subgroup analyses for septal annular velocity (SEP-e′) revealed no significant differences in treatment effect, the subgroup with SEP-e′ < 4.7 cm/s revealed a connection with reduced NT-proBNP levels in the canagliflozin group compared with the glimepiride group.